NCT02472275View on ClinicalTrials.gov

PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

August 5, 2019

Study Completion Date

August 5, 2019

Conditions
Stage I Prostate AdenocarcinomaStage II Prostate AdenocarcinomaStage III Prostate Adenocarcinoma
Interventions
DRUG

Antiandrogen Therapy

Undergo ADT with leuprolide acetate, goserelin acetate, or degarelix

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Multitargeted Tyrosine Kinase Inhibitor PLX3397

Given PO

RADIATION

Radiation Therapy

Undergo radiation therapy

Trial Locations (3)

48201

Wayne State University/Karmanos Cancer Institute, Detroit

49770

Karmanos Cancer Institute at McLaren Northern Michigan - Petoskey Radiation Oncology, Petoskey

Karmanos Cancer Institute at McLaren Northern Michigan- Petoskey Medical Oncology, Petoskey

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Barbara Ann Karmanos Cancer Institute

OTHER

NCT02472275 - PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer | Biotech Hunter | Biotech Hunter